Home > For Consumers > Antifungal drugs (azoles) for allergic...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-. doi: 10.1002/14651858.CD001108.pub2

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet].

Antifungal drugs (azoles) for allergic bronchopulmonary aspergillosis associated with asthma

This version published: 2014; Review content assessed as up-to-date: June 27, 2008.

Link to full article: [Cochrane Library]

Plain language summary

Allergic bronchopulmonary aspergillosis is a condition that complicates some people with chronic asthma. Standard treatment for this condition is high doses of oral steroids. The azole antifungal drugs attack the fungus that causes this condition and short term studies suggest that they may have some benefit when added to standard therapy.

Abstract

Background: Allergic bronchopulmonary aspergillosis is hypersensitivity to the fungus Aspergillus fumigatus that complicates patients with asthma and cystic fibrosis. The mainstay of treatment for allergic bronchopulmonary aspergillosis remains oral corticosteroids, though this does not completely prevent exacerbations and may not prevent the decline in lung function.

Objectives: The purpose of this review was to determine the efficacy of azoles in the treatment of allergic bronchopulmonary aspergillosis.

Search methods: We searched the Cochrane Airways Group Asthma trials register, CENTRAL, MEDLINE and EMBASE. Searches are current as of May 2008.

Selection criteria: All controlled trials that assessed the effect of azole antifungal agents compared to placebo or other standard therapy for allergic bronchopulmonary aspergillosis were reviewed. Patients with cystic fibrosis were not included.

Data collection and analysis: Two reviewers independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials.

Main results: Twelve trials were identified, but only three were prospective, randomised and controlled. A total of 94 participants were included. One demonstrated a reduction in immunological markers of disease activity and symptom scores using ketoconazole 400 mg daily for 12 months. There was no significant improvement in lung function. The other two examined the use of itraconazole for 16 weeks. In one there was a reduction in sputum eosinophils by 35% compared to 19% with placebo (p < 0.01). In the same trial, the number of exacerbations requiring oral corticosteroids was 0.4 per patient with itraconazole compared with 1.3 per patient with placebo (p < 0.03). Meta‐analysis of data from both trials showed that itraconazole treated patients were more likely to have decline in serum IgE over 25% or more (Peto OR 3.30; 95% confidence intervals 1.30 to 8.15).

Authors' conclusions: Itraconazole modifies the immunologic activation associated with allergic bronchopulmonary aspergillosis and improves clinical outcome, at least over the period of 16 weeks. Adrenal suppression with inhaled corticosteroids and itraconazole is a potential concern.

Editorial Group: Cochrane Airways Group.

Publication status: Edited (no change to conclusions).

Citation: Wark P, Gibson PG, Wilson A. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD001108. DOI: 10.1002/14651858.CD001108.pub2. Link to Cochrane Library. [PubMed: 15266440]

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PMID: 15266440

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...